A Proud Member of BIO

    

La Jolla Pharmaceutical Company ("La Jolla") is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions.

Lupus Clinical Trial: For information on the ASPEN Phase 3 study (Abetimus Sodium in Patients with a History of Lupus Nephritis), the ongoing Phase 3 study of Riquent (abetimus sodium), please go to the following website: clinicaltrials.gov

 



 

Terms of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company

    
WebCasts

LISTEN TO COMPANY PRESENTATION FROM CANACCORD ADAMS GLOBAL GROWTH CONFERENCE
AUGUST 12, 2008




Latest Press Releases


Link to conference call